ArticleHeliyon2024
Factors influencing economic toxicity and coping strategies in lung cancer patients: A scoping review.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The elicitation of quality of life preferences for lung cancer treatment from the perspective of patients and treating physicians: results of two discrete choice experiments.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Corylin inhibits liver cancer cell growth through the endogenous apoptosis and mitophagy.Translational cancer research · 2026Article
- A latent profile analysis of financial toxicity and its association with anxiety and depression in patients with hematologic malignancies.Asia-Pacific journal of oncology nursing · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: A scoping review aims to identify the factors that contribute to economic challenges for lung cancer patients, as well as effective responses to these challenges. This review will help in identifying lung cancer patients at risk of financial difficulties, shaping health policies, and allocating healthcare resources effectively. Data sources: This review includes both published and unpublished empirical studies. Methods: Following the scoping review guidelines set forth by the Joanna Briggs Institute (JBI), we conducted searches in databases including Pubmed, Embase, OVID, Sinomed, Web of Science, Proquest, Wanfang, and CNKI from the establishment of the repository to February 2024. We organized and analyzed the included literature. Findings: 16 papers were included in the review. We extracted assessment tools, influencing factors, and responses to economic challenges faced by lung cancer patients from the included literature. The main assessment tools for economic challenges include COST, questionnaires, medical records, burden calculations, and other relevant tools. Factors influencing economic challenges in lung cancer patients mainly include age, occupation, insurance, education, treatment, disease duration, and income. Coping strategies for economic challenges in lung cancer patients primarily include institutional, technological, and managerial reforms, as well as public education and psychological interventions. Conclusion: The prevalence of economic challenges faced by lung cancer patients is influenced by several complex factors. Healthcare professionals can develop screening tools and intervention protocols based on these influencing factors, providing a foundation for implementing targeted intervention programs for lung cancer patients at high risk of economic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.